J D D G 2012-11-01

Dimethyl fumarate - only an anti-psoriatic medication?

Markus Meissner, Eva Maria Valesky, Stefan Kippenberger, Roland Kaufmann

Index: J. Dtsch. Dermatol. Ges. 10(11) , 793-801, (2012)

Full Text: HTML

Abstract

Fumaric acid esters have been used successfully in the therapy of psoriasis vulgaris since 1959. In the last 17 years, many of the underlying mechanisms of anti-psoriatic action, such as a Th1/Th2 shift, a suppression of important leukocyte adhesion molecules, the induction of pro-apoptotic pathways in T-cells and recently anti-angiogenic action, have been discovered. Based on the knowledge of these immunomodulatory characteristics, fumaric acid esters have been shown to be effective or potentially effective in a multitude of dermatological as well as non-dermatological diseases. The range of new therapeutic targets reaches from multiple sclerosis to illnesses such as necrobiosis lipoidica, granuloma annulare and sarcoidosis. Experimental approaches offer promising, although preliminary, results on the treatment of cancer, malaria, chronic inflammatory lung diseases, and Huntington disease, to name but a few. This valued and well-known drug mainly prescribed by dermatologists is now experiencing a renaissance far beyond dermatologic applications.© The Authors • Journal compilation © Blackwell Verlag GmbH, Berlin.